A brain cancer diagnosis can be devastating to patients and their families. The statistics below are a powerful reminder of why Tocagen is seeking to provide meaningful increases in survival.
- Gliomas include all tumors arising from the supportive tissue of the brain, and account for about 80 percent of all malignant brain tumors.
- About 14,000 new cases of high grade gliomas (HGG) are expected to be diagnosed in the United States in 2016. HGG tumors include glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).
- GBM accounts for about half of all primary brain and central nervous system (CNS) cancers.
- The 1, 2 and 5-year survival rate for patients with GBM is about 37 percent, 15 percent, and 5 percent respectively, making these tumors the two most fatal forms of all primary brain and central nervous system cancers.
Source: Ostrom et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology 17:iv1 –iv62, 2015.
Tocagen is developing an investigational therapy to treat GBM and AA and is currently recruiting patients into its Phase 2/3 clinical trial, Toca 5. Learn about the Toca 5 trial.
See additional brain cancer resources below: